Companies developing a peptide-based product eventually face a make-or-buy decision: outsource manufacturing to a contract development and manufacturing organization (CDMO), or invest in building internal manufacturing capability. Each path carries distinct trade-offs worth evaluating systematically.

Factors Favoring a CDMO Relationship

  • Lower upfront capital investment, since specialized synthesis and analytical equipment is expensive to acquire and maintain
  • Access to established regulatory and quality infrastructure without building it from scratch
  • Flexibility to scale volume up or down without carrying fixed manufacturing overhead
  • Faster time to first supply, since a qualified CDMO can often begin production more quickly than a newly built internal facility

 

Factors Favoring In-House Manufacturing

  • Greater direct control over production scheduling and prioritization, particularly valuable for time-critical programs
  • Protection of proprietary process knowledge or trade secrets that a company prefers not to share with an external party
  • Potentially lower long-term unit cost at sufficient production volume once fixed investment is recovered
  • Reduced dependency risk on an external partner’s capacity availability and business continuity

 

Volume as a Central Decision Factor
Production volume is often the single most important variable in this decision; at low to moderate volumes, the fixed costs of building and maintaining in-house capability are difficult to justify compared with CDMO pricing, while at very high sustained volumes, in-house manufacturing can become more cost-effective over time.

Hybrid Approaches
Some companies pursue a hybrid strategy, using a CDMO for initial development and early-stage supply while building in-house capability in parallel for eventual commercial-scale production, or maintaining in-house capability for core, high-volume products while outsourcing specialty or lower-volume products to a CDMO.

 

Questions to Work Through Before Deciding
Companies facing this decision should realistically assess their expected production volume trajectory, the strategic importance of manufacturing control to their competitive position, their existing internal technical expertise, and their capital availability, rather than defaulting to either option without a structured evaluation.

 

Product Disclaimer & Terms of Use

IMPORTANT NOTICE: FOR RESEARCH USE ONLY (RUO)

This product is intended exclusively for laboratory research and scientific development purposes. It is NOT a drug, food, medical device, cosmetic, or diagnostic product.